发明名称 | Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis | ||
摘要 | Provided herein are methods for inhibiting tumor angiogenesis in a cancer patient, the method comprising administering to the subject an effective amount of a first isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) and an effective amount of a second isolated binding molecule which specifically binds to VEGF. | ||
申请公布号 | US8790652(B2) | 申请公布日期 | 2014.07.29 |
申请号 | US201213707299 | 申请日期 | 2012.12.06 |
申请人 | Vaccinex, Inc. | 发明人 | Basile John R.;Evans Elizabeth E.;Smith Ernest S. |
分类号 | A61K39/395;C07K16/28 | 主分类号 | A61K39/395 |
代理机构 | Thompson Coburn LLP | 代理人 | Thompson Coburn LLP |
主权项 | 1. A method for inhibiting angiogenesis in a human subject, comprising administering to the subject an effective amount of a first isolated binding molecule comprising a heavy chain variable region (VH) polypeptide comprising VH-CDR1, VH-CDR2, and VH-CDR3 amino acid sequences comprising SEQ ID NOs: 6, 7, and 8, respectively, and a light chain variable region (VL) polypeptide comprising VL-CDR1, VL-CDR2, and VL-CDR3 amino acid sequences comprising SEQ ID NOs: 14, 15 and 16, respectively, wherein the first isolated binding molecule specifically binds to semaphorin-4D (SEMA4D) and an effective amount of a second isolated binding molecule which specifically binds to VEGF and inhibits the interaction of VEGF with a VEGF receptor. | ||
地址 | Rochester NY US |